We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Drug Development in Microgravity Research Conducted Aboard Atlantis' Last Mission

By LabMedica International staff writers
Posted on 23 Jun 2010
Space Shuttle Atlantis returned from the International Space Station (ISS), landing at the Kennedy Space Center (Houston, TX, USA) May 26, 2010, with the 10th scientific payload for a commercial biotech company conducting drug development research.

Astrogenetix (Austin, TX, USA), is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS [U.S.] National Laboratory Pathfinder Vaccine (NLP-V) missions. More...
"By removing a force as fundamental as gravity in the course of this research, we're witnessing bacteria grow in ways that have not been demonstrated on Earth,” said John Porter, chief executive officer of Astrogenetix. "The use of microgravity as a new research platform will bring meaningful advancements in drug discovery and development, and we believe this early vaccine work is just the beginning.”

The company is utilizing the unique conditions of microgravity to reveal changes in bacteria, which can be targeted to create new vaccines and therapeutics. Astrogenetix has identified target genes for MRSA virulence by growing the bacteria in the microgravity environment during previous NLP-V. The company is conducting controls on this flight to validate earlier research by sending up several different strains of the bacteria, which were genetically modified to remove target genes that are believed to be associated with virulence of this organism. Moreover, the company is bringing back live forms of the bacteria that were grown in microgravity to compare to ground-based samples of the bacteria. The scientists will perform postflight analysis on the microbes to evaluate the changes that occurred on this mission.

"Each flight opportunity allows us to learn more about the bacteria and the changes that are occurring as they grow in space,” added Dr. Jeanne Becker, chief science officer for Astrogenetix. "The knowledge we're gaining can be applied to streamline and accelerate the development of vaccines and therapeutics on Earth.”

MRSA is a type of bacteria that is not responsive to commonly used antibiotics. In the United States alone, MRSA is responsible for 100,000 cases of severe infections and more than 19,000 deaths yearly. In the past 10 years, infection and mortality due to this organism has increased significantly, exceeding the death rate for HIV.

A subsidiary of Astrotech Corp., Astrogenetix, Inc. is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity.

Related Links:

Autogenetix
International Space Station National Laboratory Pathfinder Vaccine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: The method combines metagenomic sequencing with computational filtering to identify likely disease-causing bacteria and viruses (Image Credit: iStock)

Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis

Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.